|
gptkbp:instanceOf
|
gptkb:chemical_compound
antipsychotic medication
|
|
gptkbp:ATCCode
|
N05AH04
|
|
gptkbp:CASNumber
|
26615-21-4
|
|
gptkbp:compatibleWith
|
gptkb:United_Kingdom
gptkb:United_States
|
|
gptkbp:developedBy
|
gptkb:Japan
|
|
gptkbp:discoveredBy
|
gptkb:Fujisawa_Pharmaceutical
|
|
gptkbp:drugClass
|
antipsychotic medication
|
|
gptkbp:eliminationHalfLife
|
13 hours
|
|
gptkbp:hasMolecularFormula
|
C18H18N2OS
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
zotepine
|
|
gptkbp:introducedIn
|
1982
|
|
gptkbp:IUPACName
|
2-(8-chloro-6,11-dihydro-5H-dibenzo[b,e]thiepin-11-yl)-1-methylpyrrolidin-2-one
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedIn
|
gptkb:Germany
gptkb:India
gptkb:Japan
|
|
gptkbp:mechanismOfAction
|
dopamine receptor antagonist
serotonin receptor antagonist
|
|
gptkbp:pregnancyCategory
|
C (Japan)
|
|
gptkbp:proteinBinding
|
96%
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
constipation
dizziness
weight gain
sedation
tachycardia
dry mouth
extrapyramidal symptoms
|
|
gptkbp:synonym
|
gptkb:ZTP
Zotepin
Zotepina
Zotepinum
|
|
gptkbp:usedFor
|
schizophrenia
|
|
gptkbp:bfsParent
|
gptkb:N05AX
|
|
gptkbp:bfsLayer
|
7
|